XOMA (XOMA) Stock Forecast, Price & News

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for XOMA in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" XOMA shares.
View XOMA analyst ratings or view top-rated stocks.

1 Wall Street research analysts have issued 12-month price objectives for XOMA's stock. Their XOMA share price forecasts range from $69.00 to $69.00. On average, they expect the company's stock price to reach $69.00 in the next twelve months. This suggests a possible upside of 300.0% from the stock's current price.
View analysts price targets for XOMA or view top-rated stocks among Wall Street analysts.

XOMA's stock was trading at $18.40 at the beginning of 2023. Since then, XOMA shares have decreased by 6.2% and is now trading at $17.25.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our XOMA earnings forecast.

XOMA Co. (NASDAQ:XOMA) announced its quarterly earnings results on Thursday, March, 9th. The biotechnology company reported ($0.64) EPS for the quarter. The biotechnology company earned $1.49 million during the quarter, compared to the consensus estimate of $1.62 million. XOMA had a negative net margin of 774.65% and a negative trailing twelve-month return on equity of 20.65%.

11 employees have rated XOMA Chief Executive Officer John Varian on Glassdoor.com. John Varian has an approval rating of 73% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other XOMA investors own include Cytokinetics (CYTK), Alnylam Pharmaceuticals (ALNY), Ascent Solar Technologies (ASTI), CTI BioPharma (CTIC), OPKO Health (OPK), Uranium Energy (UEC), Gilead Sciences (GILD), NXP Semiconductors (NXPI) and Ekso Bionics (EKSO).

XOMA trades on the NASDAQ under the ticker symbol "XOMA."

XOMA's stock is owned by many different retail and institutional investors. Top institutional shareholders include BVF Inc. IL (31.71%), FMR LLC (10.77%), Stonepine Capital Management LLC (2.78%), Acuitas Investments LLC (0.76%), Geode Capital Management LLC (0.71%) and Susquehanna International Group LLP (0.44%). Insiders that own company stock include Bradley Sitko, Bvf Partners L P/Il, James R Neal, James R Neal, Matthew D Perry, Owen Hughes, Thomas M Burns and Value Fund L P Biotechnology.
View institutional ownership trends.

Shares of XOMA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of XOMA stock can currently be purchased for approximately $17.25.

XOMA (NASDAQ:XOMA) has a market capitalization of $197.69 million and generates $6.03 million in revenue each year. The biotechnology company earns $-17,100,000.00 in net income (profit) each year or ($2.63) on an earnings per share basis.

XOMA's mailing address is 2200 POWELL STREET SUITE 310, EMERYVILLE CA, 94608. The official website for the company is www.xoma.com. The biotechnology company can be reached via phone at (510) 204-7200, via email at jsnowden@oratoriumgroup.com, or via fax at 510-649-7571.